For example, a MAPK3/1 (ERK1/2) inhibitor, selumetinib, was more successful in improving DCM markers compared to an ACE inhibitor, benazepril, which is used as a standard cardiological treatment [56]. Here, MAPK3 is linked to familial dilated cardiomyopathy.